J&J Bedaquline and the Evolving Role for Accelerated Approval: Confirming Safety, Not Efficacy?
This article was originally published in RPM Report
Executive Summary
Discussions during an advisory committee review Janssen’s TB drug bedaquiline showed some interesting thinking around accelerated approval and how much uncertainty can be acceptable—especially when it comes to safety.